Are the Tradeoffs from Prior Authorization Worth It?
In his latest column, President and CEO Dr. Drew Altman asks if prior authorization review could be eliminated entirely, discussing how it might be done and the tradeoffs.
View the Latest: Chronic Diseases
Filter
-
-
HHS Public Health Policy Actions Under the Trump Administration 2025-2026
TrackerA comprehensive timeline of public health policy actions by the Department of Health and Human Services (HHS) under the Trump administration from 2025-2026, with key dates, descriptions, and impacts.
-
Opioid Overdose Deaths: National Trends and Variation by Demographics and States
Issue BriefOpioid overdose deaths fell sharply from 2023 to 2024 (79,358 to 54,045), driven largely by decreases in fentanyl-involved deaths. Even after these declines, deaths remained above 2019, the year before opioid deaths increased sharply during the pandemic.
-
Suicide Deaths: National Trends and Variation by Demographics and States
Issue BriefSuicide deaths fell slightly from their peak of 49,476 deaths in 2022 to 48,824 deaths in 2024, but trends by suicide method diverged: suicides by other means declined while firearm suicides reached their highest level and accounted for 57% of all suicides (up from 50% in 2014).
-
Health and Health Care for American Indian or Alaska Native People: Key Issues
Issue BriefDue to a combination of lower coverage rates, additional access barriers, and historical and ongoing discrimination, AIAN people continue to face significant disparities in health and health care.
-
New Trump Administration Health-Related Visa Guidance Could Impact Millions of Noncitizens
Issue BriefThis analysis examines the share of noncitizen and citizen adults currently living in the U.S. who have one of the health conditions identified in new State Department guidance for visa screening.
-
KFF Health Tracking Poll: Prescription Drug Costs, Views on Trump Administration Actions, and GLP-1 Use
Poll FindingAbout one in eight adults say that they are currently taking a GLP-1 drug either to lose weight or treat a chronic condition, an increase from 18 months ago, though the high costs of the medications remain a concern. Few adults think it is likely their prescription costs will go down as a result of recently announced Trump administration policies.
-
Poll: 1 in 8 Adults Say They Are Currently Taking a GLP-1 Drug for Weight Loss, Diabetes or Another Condition, Even as Half Say the Drugs Are Difficult to Afford
News ReleaseAbout one in eight adults (12%) say that they are currently taking a GLP-1 drug such as Ozempic or Wegovy either to lose weight or treat a chronic condition, an increase from 18 months ago, though the high costs of the medications remain a concern, a new KFF Health Tracking Poll finds.
-
-
KFF/ESPN Survey of 1988 NFL Players Finds the Vast Majority Say Pro Football Left Them With a Range of Serious Health Problems, but Most Would Play Again and Encourage Their Kids To Play
News ReleaseKFF and ESPN today jointly released a first-of-its-kind, in-depth polling and reporting project that sheds new light on the health issues and other challenges facing NFL players after they leave the game.